Global Cancer related Pain Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Cancer related Pain treatment during 2019. Clinical development activities are being undertaken by more than 30 companies including Alexza Pharmaceuticals Inc, AngioChem Inc, Aoxing Pharmaceutical Company Inc, Aphios Corp, Aquilus Pharmaceuticals Inc and others.
A Significant contribution to the Cancer related Pain pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Cancer related Pain pipeline included 32 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Cancer related Pain condition and increased access to investments is encouraging growth of Cancer related Pain drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Cancer related Pain drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Cancer related Pain therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Cancer related Pain pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Cancer related Pain. Further, orphan drug status, fast track designation, grants awarded and other special status for Cancer related Pain pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Cancer related Pain pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Cancer related Pain Pipeline candidates-
A Significant contribution to the Cancer related Pain pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Cancer related Pain pipeline included 32 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Cancer related Pain condition and increased access to investments is encouraging growth of Cancer related Pain drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Cancer related Pain drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Cancer related Pain therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Cancer related Pain pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Cancer related Pain. Further, orphan drug status, fast track designation, grants awarded and other special status for Cancer related Pain pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Cancer related Pain pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Cancer related Pain Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Cancer related Pain drugs
- Late phase: Phase 3 and in-approval Cancer related Pain drugs
- Company overview
- Snapshot
- Cancer related Pain therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Cancer related Pain- Disease Overview
2.2 Cancer related Pain- Pipeline Snapshot
2.3 Cancer related Pain- Pipeline Drugs by Phase
2.4 Cancer related Pain- Pipeline Drugs by Company
2.5 Cancer related Pain- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Alexza Pharmaceuticals Inc Cancer related Pain Drug Pipeline, H2- 2019
3.2 AngioChem Inc Cancer related Pain Drug Pipeline, H2- 2019
3.3 Aoxing Pharmaceutical Company Inc Cancer related Pain Drug Pipeline, H2- 2019
3.4 Aphios Corp Cancer related Pain Drug Pipeline, H2- 2019
3.5 Aquilus Pharmaceuticals Inc Cancer related Pain Drug Pipeline, H2- 2019
3.6 AstraZeneca Plc Cancer related Pain Drug Pipeline, H2- 2019
3.7 Concentric Analgesics Inc Cancer related Pain Drug Pipeline, H2- 2019
3.8 Daewoong Pharmaceutical Co Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.9 Dompe Farmaceutici SpA Cancer related Pain Drug Pipeline, H2- 2019
3.10 Fujimoto Pharmaceutical Corp Cancer related Pain Drug Pipeline, H2- 2019
3.11 Hisamitsu Pharmaceutical Co Inc Cancer related Pain Drug Pipeline, H2- 2019
3.12 Immupharma Plc Cancer related Pain Drug Pipeline, H2- 2019
3.13 India Globalization Capital Cancer related Pain Drug Pipeline, H2- 2019
3.14 Kali-Extracts Inc Cancer related Pain Drug Pipeline, H2- 2019
3.15 Klaria Pharma Holding AB Cancer related Pain Drug Pipeline, H2- 2019
3.16 Komipharm International Co Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.17 Medlab Clinical Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.18 Nanomerics Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.19 Neurocentrx Pharma Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.20 Nippon Zoki Pharmaceutical Co Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.21 Oblique Therapeutics AB Cancer related Pain Drug Pipeline, H2- 2019
3.22 Orion Corp Cancer related Pain Drug Pipeline, H2- 2019
3.23 Pfizer Inc Cancer related Pain Drug Pipeline, H2- 2019
3.24 Pharmaleads SA Cancer related Pain Drug Pipeline, H2- 2019
3.25 Plexxikon Inc Cancer related Pain Drug Pipeline, H2- 2019
3.26 Recordati SpA Cancer related Pain Drug Pipeline, H2- 2019
3.27 Ribomic Inc Cancer related Pain Drug Pipeline, H2- 2019
3.28 Sedor Pharmaceuticals LLC Cancer related Pain Drug Pipeline, H2- 2019
3.29 Sorrento Therapeutics Inc Cancer related Pain Drug Pipeline, H2- 2019
3.30 Tetra Bio-Pharma Inc Cancer related Pain Drug Pipeline, H2- 2019
3.31 Virobay Inc Cancer related Pain Drug Pipeline, H2- 2019
3.32 WEX Pharmaceuticals Inc Cancer related Pain Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Cancer related Pain- Phase 1 Drug Details
4.2 Cancer related Pain- Phase 1 Drug Overview
4.3 Cancer related Pain- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Cancer related Pain- Phase 2 Drug Details
5.2 Cancer related Pain- Phase 2 Drug Overview
5.3 Cancer related Pain- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Cancer related Pain- Phase 3 Drug Details
6.2 Cancer related Pain- Phase 3 Drug Overview
6.3 Cancer related Pain- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Cancer related Pain- Pre-clinical Phase Drug Details
7.2 Cancer related Pain- Pre-clinical Phase Drug Overview
7.3 Cancer related Pain- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Cancer related Pain- Disease Overview
2.2 Cancer related Pain- Pipeline Snapshot
2.3 Cancer related Pain- Pipeline Drugs by Phase
2.4 Cancer related Pain- Pipeline Drugs by Company
2.5 Cancer related Pain- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Alexza Pharmaceuticals Inc Cancer related Pain Drug Pipeline, H2- 2019
3.2 AngioChem Inc Cancer related Pain Drug Pipeline, H2- 2019
3.3 Aoxing Pharmaceutical Company Inc Cancer related Pain Drug Pipeline, H2- 2019
3.4 Aphios Corp Cancer related Pain Drug Pipeline, H2- 2019
3.5 Aquilus Pharmaceuticals Inc Cancer related Pain Drug Pipeline, H2- 2019
3.6 AstraZeneca Plc Cancer related Pain Drug Pipeline, H2- 2019
3.7 Concentric Analgesics Inc Cancer related Pain Drug Pipeline, H2- 2019
3.8 Daewoong Pharmaceutical Co Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.9 Dompe Farmaceutici SpA Cancer related Pain Drug Pipeline, H2- 2019
3.10 Fujimoto Pharmaceutical Corp Cancer related Pain Drug Pipeline, H2- 2019
3.11 Hisamitsu Pharmaceutical Co Inc Cancer related Pain Drug Pipeline, H2- 2019
3.12 Immupharma Plc Cancer related Pain Drug Pipeline, H2- 2019
3.13 India Globalization Capital Cancer related Pain Drug Pipeline, H2- 2019
3.14 Kali-Extracts Inc Cancer related Pain Drug Pipeline, H2- 2019
3.15 Klaria Pharma Holding AB Cancer related Pain Drug Pipeline, H2- 2019
3.16 Komipharm International Co Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.17 Medlab Clinical Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.18 Nanomerics Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.19 Neurocentrx Pharma Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.20 Nippon Zoki Pharmaceutical Co Ltd Cancer related Pain Drug Pipeline, H2- 2019
3.21 Oblique Therapeutics AB Cancer related Pain Drug Pipeline, H2- 2019
3.22 Orion Corp Cancer related Pain Drug Pipeline, H2- 2019
3.23 Pfizer Inc Cancer related Pain Drug Pipeline, H2- 2019
3.24 Pharmaleads SA Cancer related Pain Drug Pipeline, H2- 2019
3.25 Plexxikon Inc Cancer related Pain Drug Pipeline, H2- 2019
3.26 Recordati SpA Cancer related Pain Drug Pipeline, H2- 2019
3.27 Ribomic Inc Cancer related Pain Drug Pipeline, H2- 2019
3.28 Sedor Pharmaceuticals LLC Cancer related Pain Drug Pipeline, H2- 2019
3.29 Sorrento Therapeutics Inc Cancer related Pain Drug Pipeline, H2- 2019
3.30 Tetra Bio-Pharma Inc Cancer related Pain Drug Pipeline, H2- 2019
3.31 Virobay Inc Cancer related Pain Drug Pipeline, H2- 2019
3.32 WEX Pharmaceuticals Inc Cancer related Pain Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Cancer related Pain- Phase 1 Drug Details
4.2 Cancer related Pain- Phase 1 Drug Overview
4.3 Cancer related Pain- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Cancer related Pain- Phase 2 Drug Details
5.2 Cancer related Pain- Phase 2 Drug Overview
5.3 Cancer related Pain- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Cancer related Pain- Phase 3 Drug Details
6.2 Cancer related Pain- Phase 3 Drug Overview
6.3 Cancer related Pain- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Cancer related Pain- Pre-clinical Phase Drug Details
7.2 Cancer related Pain- Pre-clinical Phase Drug Overview
7.3 Cancer related Pain- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
